Elliott is extremely disappointed in your decision to accept a revised Johnson & Johnson offer that clearly fails to maximize shareholder value, and is appalled at the board's failure to stand up for the shareholders you are charged to represent.

235

We ask that you declare any subsequent offer with improved terms from Boston Scientific as superior.

200